BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15344953)

  • 61. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
    Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
    Awaya N; Adachi A; Mori T; Kamata H; Nakahara J; Yokoyama K; Yamada T; Kizaki M; Sakamoto M; Ikeda Y; Okamoto S
    Leuk Res; 2006 Aug; 30(8):1059-62. PubMed ID: 16330097
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR.
    Michelson P; Watkins B; Webber SA; Wadowsky R; Michaels MG
    Pediatr Transplant; 2008 Jun; 12(4):464-8. PubMed ID: 18466434
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Simian virus 40 in posttransplant lymphoproliferative disorders.
    Vilchez RA; Jauregui MP; Hsi ED; Novoa-Takara L; Chang CC
    Hum Pathol; 2006 Sep; 37(9):1130-6. PubMed ID: 16938517
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children.
    Gerritsen EJ; Stam ED; Hermans J; van den Berg H; Haraldsson A; van Tol MJ; van den Bergh RL; Waaijer JL; Kroes AC; Kluin PM; Vossen JM
    Bone Marrow Transplant; 1996 Aug; 18(2):377-82. PubMed ID: 8864449
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation.
    Ebihara Y; Manabe A; Tanaka R; Yoshimasu T; Ishikawa K; Iseki T; Hayakawa J; Maeda M; Asano S; Tsuji K
    Bone Marrow Transplant; 2003 Jun; 31(12):1169-71. PubMed ID: 12796798
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.
    Bordon V; Padalko E; Benoit Y; Dhooge C; Laureys G
    Pediatr Transplant; 2012 Mar; 16(2):144-50. PubMed ID: 22288846
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor.
    Morishima Y; Yabe T; Matsuo K; Kashiwase K; Inoko H; Saji H; Yamamoto K; Maruya E; Akatsuka Y; Onizuka M; Sakamaki H; Sao H; Ogawa S; Kato S; Juji T; Sasazuki T; Kodera Y;
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):315-28. PubMed ID: 17317585
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients.
    Aalto SM; Juvonen E; Tarkkanen J; Volin L; Haario H; Ruutu T; Hedman K
    Clin Infect Dis; 2007 Nov; 45(10):1305-9. PubMed ID: 17968825
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantification of Epstein-Barr virus-DNA load in lung transplant recipients: a comparison of plasma versus whole blood.
    Bakker NA; Verschuuren EA; Veeger NJ; van der Bij W; van Imhoff GW; Kallenberg CG; Hepkema BG
    J Heart Lung Transplant; 2008 Jan; 27(1):7-10. PubMed ID: 18187080
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of serum and whole blood levels of cytomegalovirus and Epstein-Barr virus DNA.
    Kullberg-Lindh C; Olofsson S; Brune M; Lindh M
    Transpl Infect Dis; 2008 Oct; 10(5):308-15. PubMed ID: 18466193
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
    Weinstock DM; Ambrossi GG; Brennan C; Kiehn TE; Jakubowski A
    Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
    [TBL] [Abstract][Full Text] [Related]  

  • 77. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
    Subklewe M; Marquis R; Choquet S; Leblond V; Garnier JL; Hetzer R; Swinnen LJ; Oertel S; Papp-Vary M; Gonzalez-Barca E; Hepkema BG; Schoenemann C; May J; Pezzutto A; Riess H
    Transplantation; 2006 Oct; 82(8):1093-100. PubMed ID: 17060859
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epstein-Barr virus-related lymphoproliferative disease complicating childhood acute lymphoblastic leukemia: no recurrence after unrelated donor bone marrow transplantation.
    Pondarré C; Kebaili K; Dijoud F; Basset T; Philippe N; Bertrand Y
    Bone Marrow Transplant; 2001 Jan; 27(1):93-5. PubMed ID: 11244444
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction.
    Kullberg-Lindh C; Ascher H; Saalman R; Olausson M; Lindh M
    Pediatr Transplant; 2006 Feb; 10(1):83-9. PubMed ID: 16499593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.